Rapid and complete hemopoietic reconstitution following combined transplantation of autologous blood and bone marrow cells. A changing role for high dose chemo-radiotherapy?
The role of high dose chemo-radiotherapy with autologous bone marrow transplantation in the treatment of neoplasia remains to be clearly defined. Because of the iatrogenic morbidity, mortality and high cost of the supportive care required during the post-transplantation period of prolonged marrow aplasia, intensive therapy remains a sophisticated procedure lacking proper evaluation in clinical trials. We report here that when autologous bone marrow cells are supplemented with a small number of peripheral blood nucleated cells collected after prior myelosuppressive chemotherapy, complete hematological recovery is so prompt that myeloid toxicity appears no longer the major limiting factor of high-dose chemo-radiotherapy. The increased therapeutic index made possible by the procedure will allow us to address the issue of whether intensive cytoreductive therapy can be useful as initial treatment of selected tumors with curative intent.
Gianni
A M
AM
Cristina Gandini Bone Marrow Transplantation Unit, Division of Medical Oncology, Istituto Nazionale Tumori, Milano, Italy.
Bregni
M
M
Siena
S
S
Villa
S
S
Sciorelli
G A
GA
Ravagnani
F
F
Pellegris
G
G
Bonadonna
G
G
D000293:Adolescent; D000328:Adult; D001803:Blood Transfusion; D001853:Bone Marrow / Q000187:drug effects / Q000528:radiation effects; D016026:Bone Marrow Transplantation; D005260:Female; D006412:Hematopoietic Stem Cells / Q000502:physiology*; D006801:Humans; D008297:Male; D008558:Melphalan / Q000009:adverse effects; D008875:Middle Aged; D009369:Neoplasms / Q000628:therapy*; D011878:Radiotherapy / Q000009:adverse effects
D008558:Melphalan